Tranexamic Acid in Gastrointestinal Bleeding

Tranexamic Acid in Gastrointestinal Bleeding

Extended-use high-dose IV tranexamic acid does not improve mortality or bleeding outcomes and increases adverse events. Low-dose/enteral tranexamic acid may be effective in reducing hemorrhage; more evidence is required to... read more

Risk of Serious Blood Clots Up To 6 Months After COVID-19

Risk of Serious Blood Clots Up To 6 Months After COVID-19

A study from Sweden finds an increased risk of deep vein thrombosis (a blood clot in the leg) up to three months after COVID-19 infection, pulmonary embolism (a blood clot in the lung) up to six months, and a bleeding event... read more

Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19

Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19

Among critically ill patients with COVID-19, treatment with an antiplatelet agent, compared with no antiplatelet agent, had a low likelihood of providing improvement in the number of organ support–free days within 21 days. The... read more

tPA for Critically Ill ICU Patients with COVID-19: Does Alteplase Help?

tPA for Critically Ill ICU Patients with COVID-19: Does Alteplase Help?

How do you define a last-ditch effort to save someone's life from COVID-19? Perhaps giving tPA to a severe COVID patient? At this point, I am certain many of us have attempted, with informed consent of course, therapies for... read more

Thromboinflammation and Antithrombotics in COVID-19

Thromboinflammation and Antithrombotics in COVID-19

Thrombotic complications of SARS-CoV-2 infection were recognized early in the pandemic, when infected patients often presented with abnormal coagulation findings and acute macrovascular obstruction, and evidence of pulmonary... read more

Anticoagulation in COVID-19 Patients

Anticoagulation in COVID-19 Patients

Clinical, laboratory, and autopsy findings support an association between COVID-19 and thromboembolic disease. Acute COVID-19 infection is characterized by mononuclear cell reactivity and pan-endothelialitis, contributing... read more

Ascending Aortic Thrombus After COVID-19 Infection

Ascending Aortic Thrombus After COVID-19 Infection

SARS-CoV-2 predisposes patients to both venous and arterial thromboembolism, including ascending aortic thrombus. The current guidelines for anticoagulation recommend three to six months of continuous anticoagulation... read more

Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia

Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia

Vaccine-induced immune thrombotic thrombocytopenia is a serious complication of vaccination that is not feasible to anticipate or prevent. When the patient presents with sustained headache, neurologic symptoms/signs,... read more

A New Risk Assessment Model for Hospital-Acquired Venous Thromboembolism in Critically Ill Children

A New Risk Assessment Model for Hospital-Acquired Venous Thromboembolism in Critically Ill Children

Using the multicenter Children’s Hospital-Acquired Thrombosis registry, we identified five independent risk factors for hospital-acquired venous thromboembolism in critically ill children, deriving a new hospital-acquired... read more

Subclavian vs. Femoral Arterial Cannulations During ECMO

Subclavian vs. Femoral Arterial Cannulations During ECMO

During peripheral extracorporeal veno-arterial membrane oxygenation (VA-ECMO) support, subclavian arterial cannulation provides, in comparison to femoral arterial cannulation, an anterograde flow which may prevent from left... read more

Anticoagulation in COVID-19

Anticoagulation in COVID-19

Thrombotic complications (arterial and venous) are common in patients admitted to hospital with COVID-19 and are an independent predictor of poor outcome. Microvascular thrombi also contribute to organ dysfunction, including... read more

Obesity, Inflammatory and Thrombotic Markers, and Major Clinical Outcomes in Critically Ill Patients with COVID-19 in the US

Obesity, Inflammatory and Thrombotic Markers, and Major Clinical Outcomes in Critically Ill Patients with COVID-19 in the US

In critically ill patients with COVID-19, higher BMI was not associated with death or thrombotic events but was associated with a greater risk of ARDS and AKI-RRT. The lack of an association between BMI and circulating... read more

ARDS and High Blood Endocan Profile During COVID‑19

ARDS and High Blood Endocan Profile During COVID‑19

With great interest, we read the recently published paper by Pascreau et al. concluding that a high blood endocan profile during COVID‑19 distinguishes moderate from severe acute respiratory distress syndrome (ARDS). In... read more

Outcomes of Catheter-Related Arterial and Venous Thrombosis After Enoxaparin Therapy in Neonates and Infants With Congenital Heart Disease

Outcomes of Catheter-Related Arterial and Venous Thrombosis After Enoxaparin Therapy in Neonates and Infants With Congenital Heart Disease

A high proportion of vascular catheter-related thrombi identified in infants with congenital heart disease resolve with enoxaparin treatment. In all patients with thrombosis, arterial versus venous thrombosis is associated... read more